SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (2315)9/8/1997 5:49:00 PM
From: biowa   of 9719
 
V1,

>>On the GZTC front do you think that the FDA approval process will be expedited for future products once they get through the process a couple of times.<<

I am trying to temper my enthusiasm because if transgenic production becomes a standard for geneticallly engineered and plasma protiens then the potential valuation for this company is making me dizzy.<<

Can't have you getting dizzy; you might drop the baby. <g> I think the FDA will want to be very sure that they cover the issues we've talked about very thoroughly before they accept transgenic production as just another process alternative. Then, IMO, approval times will begin to depend solely on the underlying molecule/indication.

If you're looking for tempering, remember that there are competitors, some who, with cloning, may have lead time and cost advantages over GZTC. And there is always the potential of plant transgenics for making lower cost alternatives. And where there's success, there will be money to accelerate the development of competitors.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News